JAMM Therapeutics is developing small molecule inhibitors of the cytosolic deubiquitinating BRISC complex to treat Type I Interferonopathies.

Scientific approach

BRISC is an important regulator of Type I Interferon. It can stabilize IFNAR1 (a subunit of the Type I Interferon receptor) and thus promote Interferon-dependent responses. Type I Interferons are a central mediator in systemic lupus erythematosus (SLE).

link to JAMM Therapeutics page

Indications

Systemic lupus erythematosus (SLE)

Team

Prof. Roger Greenberg, PhD, Co-inventor and advisor

Elton Zeqiraj, PhD, Co-inventor and advisor

Prof. Joe Salvino, PhD, Co-inventor

Doron Levin, PhD, CSO

Scroll to top